Lastly, a mutation in the K128 and K190 residues in Bax reduced the ubiquitination of Bax itself, and it was confirmed that this mutation regulates the half-life of Bax (Figure 4), thus defining the increased stability of the Bax protein as a potential target for promoting cell death in cancer cells and therapeutic development. Here, BAX is linked to cancer.